09966 ALPHAMAB-B
- 2.720
- +0.150+5.84%
ALPHAMAB-B News
Express News | Alphamab Oncology - Collaboration With Arrivent for Research, Development and Commercialization of ADC Products
Hong Kong Stock Market Movement| Concorde Pharmacy-B (09966) soared by 19%, clinical research on the treatment of late-stage solid tumors showed good tolerance
Zhixun Finance learned from the APP that Kangning Jerry Pharmaceuticals B (09966) surged 19%. As of press time, it rose 19.08% to HK$3.02, with a turnover of HK$87.057 million. On the news side, Kangning Jerry Pharmaceuticals recently announced that the Phase I clinical study data of its new HER2-targeting bispecific antibody conjugate (ADC) JSKN003 for HER2-expressing solid tumors in China will be first released at the 2024 ASCO Annual Meeting. The research conclusion shows that JSKN003 has good tolerability and in patients with advanced/metastatic solid tumors who have previously undergone multiple lines of systemic treatment.
China's clinical research data for the Kangningjeri HER2 bispecific antibody drug JSKN003 was first presented at the 2024 ASCO Annual Meeting.
The Phase I clinical study results of JSKN003-102 were reported at this year's ASCO Annual Meeting. JSKN003 has good tolerability and controllable safety in advanced/metastatic solid tumor patients receiving previous multi-line system treatments, and has shown encouraging anti-tumor activity during the dose escalation period. Suzhou, June 3, 2024 / PRNewswire/ -- Concorde Jerry Biopharmaceuticals (stock code: 9966.HK) announced the Phase I clinical research data (study number: JSKN003) of HER2 bispecific antibody drug JSKN003 for the treatment of HER2-expressing solid tumors in China.
Alphamab Presents Results of Phase 1/2 China Trial for Tumor Drug in US Oncology Meeting
Alphamab Oncology (HKG:9966) presented the results of a phase 1/2 clinical study of its JSKN003 drug for Chinese patients with advanced solid tumors at the American Society of Clinical Oncology meetin
Corning Jerry Pharmaceutical-B (09966.HK): The latest findings of the JSKN003 Phase I/II clinical study on advanced solid tumors presented at the 2024 ASCO Annual Meeting
On June 3, GLONGHUI | Corning Jerry Pharmaceutical-B (09966.HK) announced that the results of the JSKN003 phase I/ II clinical study (study number: JSKN003-102) (“JSKN003-102”) for patients with advanced solid tumors were announced during the 2024 ASCO Annual Meeting poster presentation (abstract number: 3031; poster number: 176), and the results of this study were also published on the company's website.
Changes in Hong Kong stocks | Corning Jerry Pharmaceutical-B (09966) continues to fall 6%, KN046-303 clinical trial failed
Corning Jerry Pharmaceutical-B (09966) continued to drop 6%, and the stock closed down nearly 45% yesterday. As of press release, it decreased by 6.08% to HK$2.47, with a turnover of HK$396.06 million.
Alphamab's Phase 3 Trial for Pancreatic Cancer Treatment Fails to Reach Preset Statistical Endpoint; Shares Plunge 38%
Alphamab Oncology's (HKG:9966) phase 3 clinical trial for the combination of the KN046 drug with nab-paclitaxel/gemcitabine for the treatment of unresectable or metastatic pancreatic ductal adenocarci
Changes in Hong Kong stocks | Corning Jerry Pharmaceutical-B (09966) opened nearly 15% lower, and the overall survival results of the KN046-303 trial did not reach the intended end point
Corning Jerry Pharmaceutical-B (09966) opened nearly 15% lower in early trading. As of press release, it decreased by 14.92% to HK$4.05, with a turnover of HK$1,846,800.
Corning Jerry Pharmaceutical-B (09966): The KN046-303 trial has reached the pre-set number of deaths
Corning Jerry Pharmaceutical-B (09966) announced the latest developments relating to KN046-303, KN046...
Corning Jerry Pharmaceutical-B (09966.HK) issued 80,000 shares due to the exercise of share options
On May 28, GLONGHUI | Corning Jerry Pharmaceutical-B (09966.HK) announced that on May 28, 2024, 80,000 shares will be issued in accordance with the pre-initial public sale share option plan 2 adopted on March 29, 2019.
Corning Jerry completes first patient administration in phase I clinical study of HER3/TROP2 dual antibody ADC drug JSKN016
SUZHOU, May 22, 2024/PRNewswire/ -- Corning Jerry Biopharmaceuticals (stock code: 9966.HK) announced that the Phase I clinical study (study number: JSKN016-101) of the HER3/TROP2 dual-antibody ADC drug JSKN016 in patients with advanced malignant solid tumors in China has completed its first patient administration. TROP2 (Trophoblast cell surface antigen 2, human trophoblast cell surface antigen 2) is widely expressed in solid tumors, and its upregulation can promote tumor growth
Corning Jerry Pharmaceutical-B (09966): Phase I clinical trial of JSKN016 to treat advanced malignant solid tumors completed first patient administration
Corning Jerry Pharmaceutical-B (09966) announced that JSKN016 (a human epidermal growth factor independently developed by the company...
Alphamab Oncology's (HKG:9966) 28% Share Price Surge Not Quite Adding Up
Alphamab Oncology (HKG:9966) shares have had a really impressive month, gaining 28% after a shaky period beforehand. Unfortunately, the gains of the last month did little to right the losses of the
Corning Jerry will first announce Chinese clinical study data on JSKN003 treatment of HER2-expressing solid tumors at the 2024 ASCO Annual Meeting
SUZHOU, May 6, 2024/PRNewswire/ -- Corning Jerry Biopharmaceuticals (stock code: 9966.HK) announced that the company will first announce the Chinese clinical study data (study number: JSKN003-102) of the HER2 double antagonist conjugate drug JSKN003 to treat HER2-expressing solid tumors at the 2024 American Society of Clinical Oncology (ASCO) annual meeting. This year's ASCO Annual Meeting will be held in Chicago, USA from May 31 to June 4, 2024, local time. Topic: Safety and pharmacokinetics of JSKN003 in patients with advanced solid tumors
Alphamab Oncology's 2023 Loss Narrows as Revenue Rises
Alphamab Oncology's (HKG:9966) loss narrowed to 210.6 million yuan, or 0.22 yuan per share, in 2023 from 325.7 million yuan, or 0.35 yuan per share, in 2022, according to the company's annual report f
康寧傑瑞製藥-B：2023年報
Corning Jerry Pharmaceutical-B (09966.HK) grants 1.18 million share options
Glonghui, April 23 | Corning Jerry Pharmaceutical-B (09966.HK) announced that on April 23, 2024, according to the initial public offering after-sales share option plan, the company has decided to grant 1.18 million share options to four eligible participants (that is, employees of the Group), at an exercise price of HK$4.350 per share. Under the restricted share award scheme, the company has decided to award a total of 130,000 award shares to two eligible participants (i.e. employees of the Group). The purpose of granting share options and rewarding shares is to: (i) recognize the share option grantor and reward the grantee's contributions to the Group; (i
Alphamab Oncology Presents Phase-I Clinical Trial Results at 2024 AACR Annual Meeting
Alphamab Oncology (HKG:9966) said it presented the phase-I clinical trial results of its cancer drug during a poster session at the American Association for Cancer Research annual meeting, according t
HER2 dual antibody ADC drug JSKN003 Australian Phase I clinical study data unveiled at 2024 AACR annual meeting
The findings of JSKN003 during the dose escalation period (Ia) were reported at this AACR conference. The treatment of advanced HER2 expression/metastatic solid tumors with JSKN003 showed encouraging efficacy signals, with an ORR of 100% in patients with HER2-positive breast cancer. The tolerability and safety are good, DLT has not occurred, and MTD has not been achieved. Suzhou, China, April 10, 2024 /PRNewswire/ -- Corning Jerry Biopharmaceuticals (stock code: 9966.HK) announced the company at the 2024 American Association for Cancer Research Annual Meeting (AACR 2024)
Corning Jerry Pharmaceutical-B (09966.HK): The latest results of the Phase I clinical study of JSKN003 for the treatment of advanced solid tumors with advanced HER2 expression presented at the 2024 AACR Annual Meeting
Gelonghui, April 10, 丨 Corning Jerry Pharmaceutical-B (09966.HK) announced that the results of the JSKN003 Phase I clinical study (study number: JSKN003-101) (“JSKN003-101”) for the treatment of patients with advanced/metastatic solid tumors (poster board number: 7; abstract number: CT179) were presented during the poster presentation period at the 2024 AACR Annual Conference held from April 5 to April 10, 2024.
Analysis
Price Target
No Data
